Dyslipidemia Therapeutics Market
Dyslipidemia Therapeutics Market By Type (Low-density Lipoproteins (LDL), Triglycerides), By Drug Class (Statins, Non-Statins), By Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Stores) & By Region - Global Market Insights 2023 to 2033
Analysis of Dyslipidemia Therapeutics Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Dyslipidemia Therapeutics Market Outlook (2023 to 2033)
The global dyslipidemia therapeutics market is valued at US$ 41.55 billion in 2023 and is forecasted to exhibit expansion at a CAGR of 2.5% over the next ten years. This Fact.MR market study predicts global demand for dyslipidemia therapeutics to accumulate a market revenue of US$ 53.2 billion by the end of 2033.
Cholesterol plays a crucial role in the health of an individual and an imbalance of low-density lipoprotein cholesterol, (LDL-C), high-density lipoprotein (HDL), and triglycerides cause dyslipidemia, which further leads to the development of cardiovascular disorders.
Improper eating habits, adoption of a sedentary lifestyle, and lack of physical activity are key prospects that are anticipated to foster demand for dyslipidemia therapeutics in the future. High consumption of alcohol and tobacco is also anticipated to increase the risk of dyslipidemia and boost dyslipidemia drug sales throughout the forecast period.
Supportive government initiatives to boost awareness regarding dyslipidemia and surging investments in medical research are other key aspects that could further bolster dyslipidemia therapeutics demand over the next ten years. The expanding aging population around the world is also anticipated to be a key prospect that could influentially alter the consumption of dyslipidemia therapeutics throughout the forecast period and beyond.
Dyslipidemia has been associated with an increased risk of ischemic heart diseases that are witnessing a notable hike in incidence in recent years and have been known to claim many lives around the world as well.
- As per a study published on the National Institutes of Health website, nearly 1.72% population of the world is affected by ischemic heart diseases with Eastern European countries expected to lead in terms of prevalence in the future.
On the flip side, lack of awareness regarding dyslipidemia and the presence of stringent regulatory mandates for new drug approvals around the world are anticipated to constrain dyslipidemia therapeutics consumption trends in the long run. The high initial cost of development and research for dyslipidemia therapeutics formulation is also projected to obstruct market growth to a certain extent. However, increasing healthcare expenditure around the world is also predicted to create an opportune business scope for dyslipidemia therapeutics vendors going forward.
An elaborative assessment of local supply, product standards, safety regulations, and other influential aspects has been discussed extensively in this recently updated dyslipidemia therapeutics market research study by Fact.MR, a market research and competitive intelligence provider.
Dyslipidemia Therapeutics Market Size (2023)
US$ 41.55 Billion
Projected Market Value (2033F)
US$ 53.2 Billion
Global Market Growth Rate (2023 to 2033)
Authoritative Regional Market
Key Companies Profiled
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What Role Will New Companies Play in Determining the Future of Dyslipidemia Therapeutics?
“Development of Novel Cholesterol-lowering Solutions”
Aspiring dyslipidemia therapeutics providers are anticipated to focus on research and development of novel dyslipidemia drugs and medications that reduce cholesterol. Start-ups are approaching dyslipidemia from unique angles while developing products that not only help in the treatment of dyslipidemia but could also be able to prevent it from developing in people.
- In September 2021, researchers from a Brazilian start-up called Crop Biotecnologia, revealed that they had developed a new platform to express peptides in tomatoes to use them in dyslipidemia treatment and other chronic disease treatments. The peptide can reduce bad cholesterol (LDL) levels by inhibiting the PCSK9 protein that breaks down LDL receptors.
- 89Bio Inc., a biotechnology company founded in 2018, is also focusing on the development of its new drug called pegozafermin, which could address the need for efficacious therapies for hypertriglyceridemia and revolutionize the global dyslipidemia marketplace in the future.
New dyslipidemia therapeutics manufacturers are also focusing on raising new capital to fund their business expansion efforts and channel more investments in their R&D sector.
- In September 2020, Gruthan Bioscience LLC, a start-up founded by a researcher at the Medical University of South Carolina, was awarded a Small Business Transfer (STTR) award from the National, Heart, Blood, and Lung Institute. The new company was expected to develop novel cholesterol-lowering drugs.
An elaborative account of the current and forecasted start-up scenario on a global and regional level has been exclusively discussed in this latest dyslipidemia therapeutics research study by skilled analysts at Fact.MR.
Why Should Dyslipidemia Therapeutics Suppliers Target the United States?
“High Prevalence of Obesity in the Country”
Obesity has become a major public health issue for the population of the United States and this is projected to be a prime factor that is estimated to benefit dyslipidemia therapeutics shipments across the forecast period. Moreover, the presence of developed healthcare infrastructure and key pharmaceutical manufacturing companies are also expected to favor market development over the next ten years.
Increasing investments in medical R&D, a growing geriatric population, rising cases of cardiovascular disorders, and surging consumption of nutraceuticals in the country are other key aspects that could augment the consumption of dyslipidemia medication in the future. Surging cases of diabetes are also expected to create an opportune market scenario for dyslipidemia therapeutics companies and provide lucrative business scope going forward.
Will Japan Be an Investment-worthy Space for Dyslipidemia Therapeutic Providers?
“Rapidly Expanding Senescent Population Propelling Dyslipidemia Therapeutics Demand”
The healthcare industry of Japan is largely driven by its increasing aging population, which is estimated to account for more than 1/3 of its total population at present. Elder people are more at risk of being affected by cardiovascular disorders and this is a key factor that could provide highly lucrative opportunities for dyslipidemia therapeutics companies in the future.
Increasing investments in healthcare infrastructure development in the country are also expected to fuel sales of heart failure therapeutics and HDL therapeutics across the forecast period and beyond. However, low obesity and less consumption of saturated fats in Japan as compared to countries such as the United States contribute to a lower incidence of cardiovascular diseases, which could temporarily prove to be a disadvantage for dyslipidemia therapeutics suppliers in the country.
Changing dietary preferences, the increasing influence of Western culture, and steadily increasing obesity coupled with a rising number of elder people are expected to create highly remunerative business opportunities by the end of the forecast period.
What Prospects are Driving Demand for Dyslipidemia Therapeutics in Europe?
“High Incidence of Cardiovascular Diseases and Increasing Approval of Novel Therapeutics”
European countries have been witnessing a notable hike in the incidence of cardiovascular disorders and this is anticipated to significantly boost demand for dyslipidemia therapeutics over the coming years. The high prevalence of chronic disorders, the increasing number of people being affected by obesity and diabetes, growing aging population, and increasing healthcare expenditure are other key aspects that are common for dyslipidemia therapeutics demand in almost all European countries.
Increasing number of approvals for novel dyslipidemia drugs in European countries and the growing availability of novel dyslipidemia therapeutics are also expected to crucial augment sales growth over the next ten years. Germany and Russia are anticipated to provide highly lucrative business opportunities for dyslipidemia therapeutics suppliers in the future.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Which Channel Leads Dyslipidemia Therapeutics Sales?
“Hospital Pharmacies Accounting for Authoritative Market Share”
Based on distribution channel, the dyslipidemia therapeutics market is segmented into hospital pharmacies, drug stores, retail stores, and mail order pharmacies.
The surging rate of hospitalization and an increasing number of dyslipidemia treatments being performed in hospital settings are projected to bolster sales of dyslipidemia therapeutics from hospital pharmacies over the coming years. The growing availability of novel treatments in hospitals is also a key factor promoting dyslipidemia drug sales through hospital pharmacies across the forecast period.
Sales of dyslipidemia therapeutics through mail order pharmacies are anticipated to have a bright outlook in the future owing to increasing medical tourism and growing demand for novel treatment procedures around the world.
Prime dyslipidemia therapeutics companies are focusing on launching new products and expanding their business scope around the world. Dyslipidemia drug providers are also hastening the launch of these novel drugs by filing for approval with regulatory authorities and trying to gain a competitive advantage by getting approved before their competitors.
- In May 2022, Zydus Lifesciences Limited, an Indian pharmaceutical manufacturing company, announced the regulatory filing of its new drug called Bemdac which was expected to be used for the treatment of patients affected with uncontrolled LDL-cholesterol (LDL-c). The product on approval was expected to be a crucial addition to Zydus’s dyslipidemia and cardiovascular medication portfolio.
Additional information about new developments by top dyslipidemia therapeutics producers such as Merck & Co., Mylan, AstraZeneca, Novartis AG, Pfizer, etc., and how they influence aspects such as product standards and pricing trends have been examined closely in this revised Fact.MR research analysis.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Key Segments of Dyslipidemia Therapeutics Industry Research
By Type :
- Low-density Lipoproteins (LDL)
By Drug Class :
- PCSK9 Inhibitors
- Cholesterol Absorption Inhibitors
- Bile Acid Resins
- Combination Drugs
By Distribution Channel :
- Hospital Pharmacies
- Drug Stores
- Retail Stores
- Mail Order Pharmacies
By Region :
- North America
- Latin America
- FAQs -
The global dyslipidemia therapeutics market stands at US$ 41.55 billion in 2023.
Dyslipidemia therapeutics demand is set to rake in revenue worth US$ 53.2 billion by the end of 2033.
Over the next ten years, worldwide revenue from dyslipidemia therapeutics is expected to rise at 2.5% CAGR.
Demand for dyslipidemia therapeutics in North America accounts for a commanding share of the global market at present.
AstraZeneca, Novartis AG, Abbot Laboratories, Amgen, and Kowa Pharmaceuticals America Inc. are leading dyslipidemia therapeutics suppliers.